Seric factors influence cell cycle modifications during commitment of murine erythroleukemia cells to differentiation.
Cell cycle modifications are among the early events which take place during the induced differentiation of murine erythroleukemia (MEL) cells; a transient accumulation of the cells in the G1 phase of the cell cycle, followed by a re-entry of the cells into a proliferation state, has been described. In order to characterize a putative role of serum in such variations, we have studied the modifications of the cell cycle parameters when cells were induced to differentiate in the presence or in the absence of seric factors. We show that, in the absence of exogenous factors brought by serum, the G1 accumulation was enhanced both in amplitude and in duration, but cells were still able to bypass the G1 block and re-enter into the S phase. These results indicate that the resumption of cell proliferation after the transient block is under synergistic control of seric and endogenous factors, but these later are sufficient to overcome the block. However, MEL cells were unable to differentiate in the absence of seric factors, as measured by the number of benzidine-positive cells during induction with hexamethylene-bisacetamide (HMBA) or butyric acid. This capacity to differentiate was recovered when serum was added back to the culture medium, and the efficiency of recovery was maximal when cells underwent a full round of DNA replication in the presence of serum after the G1 block. The analysis of two molecular markers of cell differentiation confirmed these results.
Mencherini
F
F
INSERM Unité 309, Département de Biologie Moléculaire et Structurale, Centre d'Etudes Nucléaires de Grenoble.
Khochbin
S
S
Chabanas
A
A
Lawrence
J J
JJ
D000081:Acetamides / Q000494:pharmacology; D000818:Animals; D014408:Biomarkers, Tumor; D001798:Blood Proteins / Q000502:physiology*; D015152:Blotting, Northern; D002087:Butyrates / Q000494:pharmacology; D002453:Cell Cycle / Q000502:physiology; D002455:Cell Division / Q000502:physiology; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D004261:DNA Replication; D004273:DNA, Neoplasm / Q000032:analysis / Q000235:genetics; D016193:G1 Phase / Q000502:physiology; D006397:Hematinics / Q000494:pharmacology; D004915:Leukemia, Erythroblastic, Acute / Q000235:genetics / Q000473:pathology*; D007942:Leukemia, Experimental / Q000235:genetics / Q000473:pathology*; D051379:Mice; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D012334:RNA, Neoplasm / Q000032:analysis / Q000235:genetics; D016196:S Phase / Q000502:physiology; D014407:Tumor Cells, Cultured / Q000473:pathology
D000081:Acetamides; D014408:Biomarkers, Tumor; D001798:Blood Proteins; D002087:Butyrates; D004273:DNA, Neoplasm; D006397:Hematinics; D012333:RNA, Messenger; D012334:RNA, Neoplasm; C014026:hexamethylene bisacetamide